Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
作者信息
Ranger Amita, Haji Ruby, Kaczmarski Richard, Danga Akila
机构信息
Hillingdon Hospitals NHS Foundation Trust, Uxbridge, UK.
Department of Haematology, Hillingdon Hospitals, Hillingdon, UK.
出版信息
Br J Haematol. 2020 Aug;190(3):e128-e130. doi: 10.1111/bjh.16901. Epub 2020 Jun 26.
Abstract
摘要
相似文献
1
Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.白细胞介素-6阻断治疗用于一名慢性髓性白血病控制不佳患者的新型冠状病毒肺炎相关细胞因子释放综合征
Br J Haematol. 2020 Aug;190(3):e128-e130. doi: 10.1111/bjh.16901. Epub 2020 Jun 26.
2
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.新型冠状病毒肺炎相关细胞因子风暴综合征的改善：与嵌合抗原受体T细胞细胞因子释放综合征的相似之处
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
3
Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.在用托珠单抗治疗的肾移植受者中，细胞因子释放综合征迅速缓解，重症 COVID-19 临床病程良好。
Kidney Int. 2020 Aug;98(2):508-509. doi: 10.1016/j.kint.2020.05.022. Epub 2020 Jun 4.
4
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.托珠单抗治疗 COVID-19 住院患者细胞因子释放综合征：生存和临床结局。
Chest. 2020 Oct;158(4):1397-1408. doi: 10.1016/j.chest.2020.06.006. Epub 2020 Jun 15.
5
On the Alert for Cytokine Storm: Immunopathology in COVID-19.警惕细胞因子风暴：COVID-19 的免疫病理学。
Arthritis Rheumatol. 2020 Jul;72(7):1059-1063. doi: 10.1002/art.41285. Epub 2020 May 10.
6
Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.视神经脊髓炎谱系障碍患者在新冠疫情期间的免疫抑制：一项新挑战。
Mult Scler Relat Disord. 2020 Jun;41:102097. doi: 10.1016/j.msard.2020.102097. Epub 2020 Apr 5.
7
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.直面争议：白细胞介素-6 与 COVID-19 细胞因子风暴综合征。
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.03006-2020. Print 2020 Oct.
8
A plea for the pathogenic role of immune complexes in severe Covid-19.关于免疫复合物在重症新型冠状病毒肺炎中致病作用的呼吁。
Clin Immunol. 2020 Aug;217:108493. doi: 10.1016/j.clim.2020.108493. Epub 2020 Jun 8.
9
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.首例多发性骨髓瘤合并 COVID-19 患者经托珠单抗治疗后成功缓解。
Blood Adv. 2020 Apr 14;4(7):1307-1310. doi: 10.1182/bloodadvances.2020001907.
10
Is a "Cytokine Storm" Relevant to COVID-19?“细胞因子风暴”与新冠病毒病有关吗？
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154. doi: 10.1001/jamainternmed.2020.3313.
引用本文的文献
1
Co-occurrence of CML Blast Crisis and Severe COVID 19 Infection: A Case Report.慢性粒细胞白血病急变期与重症新型冠状病毒肺炎感染并存：一例报告
Cureus. 2022 Jul 14;14(7):e26865. doi: 10.7759/cureus.26865. eCollection 2022 Jul.
2
Special case of a patient in the blast phase of chronic myeloid leukemia successfully treated with tocilizumab during critical SARS-CoV-2 infection.慢性髓性白血病急变期患者在严重 SARS-CoV-2 感染期间成功接受托珠单抗治疗的特殊病例。
J Int Med Res. 2022 Mar;50(3):3000605221082875. doi: 10.1177/03000605221082875.
3
Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.间充质干细胞在急性呼吸窘迫综合征中的治疗机制揭示了其在新冠治疗中的潜力。
J Transl Med. 2021 May 10;19(1):198. doi: 10.1186/s12967-021-02862-x.
4
Immune reactivity during COVID-19: Implications for treatment.COVID-19 期间的免疫反应：对治疗的影响。
Immunol Lett. 2021 Mar;231:28-34. doi: 10.1016/j.imlet.2021.01.001. Epub 2021 Jan 6.
本文引用的文献
1
Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma.白细胞介素6阻断疗法治疗两名多发性骨髓瘤患者的重症新型冠状病毒肺炎
Br J Haematol. 2020 Jul;190(1):e9-e11. doi: 10.1111/bjh.16787. Epub 2020 May 18.
2
Tocilizumab treatment in COVID-19: A single center experience.托珠单抗治疗 COVID-19：单中心经验。
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
3
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.首例多发性骨髓瘤合并 COVID-19 患者经托珠单抗治疗后成功缓解。
Blood Adv. 2020 Apr 14;4(7):1307-1310. doi: 10.1182/bloodadvances.2020001907.
4
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China.中国武汉 2019 年冠状病毒病（COVID-19）患者免疫反应失调。
Clin Infect Dis. 2020 Jul 28;71(15):762-768. doi: 10.1093/cid/ciaa248.
5
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
6
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
7
The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis.降钙素原对菌血症的诊断准确性：系统评价和荟萃分析。
Clin Microbiol Infect. 2015 May;21(5):474-81. doi: 10.1016/j.cmi.2014.12.026. Epub 2015 Jan 14.
8
IL-6 in inflammation, immunity, and disease.白细胞介素-6在炎症、免疫及疾病中的作用
Cold Spring Harb Perspect Biol. 2014 Sep 4;6(10):a016295. doi: 10.1101/cshperspect.a016295.
9
Can we still refuse ICU admission of patients with hematological malignancies?我们还能拒绝收治血液系统恶性肿瘤患者进入重症监护病房吗？
Intensive Care Med. 2008 May;34(5):790-2. doi: 10.1007/s00134-008-1003-1. Epub 2008 Jan 24.
Zotero 插件